XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion the drug generated in 2021. every eight weeks for the 90 mg dose, according to the manufacturer. billion in 2022, a 23.43

Sales 96

Sales Manufacturing FDA Approval Life Science 96

The Pharma Data

NOVEMBER 5, 2020

About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

The Pharma Data

DECEMBER 23, 2020

During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52